Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review

Vansteenkiste, Johan; Fischer, Barbara; Dooms, Christophe; Mortensen, Jann

doi:10.1016/s1470-2045(04)01564-5

Cited by 208 publications

(146 citation statements)

References 42 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…PET/CT should be used for RT planning in NSCLC because it more accurately images tumor extent than CT alone [73], This is proven by a large surgical literature on the accuracy of FDG-PET in the lymph node staging of NSCLC [10,68,74,75].…”

Section: Tumor Movementmentioning

confidence: 99%

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007

MacManus

Nestle

Rosenzweig

et al. 2009

Radiotherapy and Oncology

333

197

View full text Add to dashboard Cite

show abstract

Section: Tumor Movementmentioning

confidence: 99%

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007

MacManus

Nestle

Rosenzweig

et al. 2009

Radiotherapy and Oncology

333

197

View full text Add to dashboard Cite

show abstract

“…Moreover, inorganic nanocarriers serve as multifunctional platforms for drug/gene delivery, targeted/controlled release, and hyperthermia to overcome cancer MDR. Furthermore, the imaging function of inorganic nanocarriers can help to investigate the biological processes by molecular imaging, including the interaction between inorganic nanocarriers and cancer cells, identifying MDR related factors, tracing the pathway of drugs/nanocarriers inside cancer cells and tumor tissues, and monitoring therapeutic outcomes 143, 144…”

Section: Conclusion and Perspectivementioning

confidence: 99%

Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics

et al. 2016

View full text Add to dashboard Cite

Cancer multidrug resistance (MDR) could lead to therapeutic failure of chemotherapy and radiotherapy, and has become one of the main obstacles to successful cancer treatment. Some advanced drug delivery platforms, such as inorganic nanocarriers, demonstrate a high potential for cancer theranostic to overcome the cancer‐specific limitation of conventional low‐molecular‐weight anticancer agents and imaging probes. Specifically, it could achieve synergetic therapeutic effects, demonstrating stronger killing effects to MDR cancer cells by combining the inorganic nanocarriers with other treatment manners, such as RNA interference and thermal therapy. Moreover, the inorganic nanocarriers could provide imaging functions to help monitor treatment responses, e.g., drug resistance and therapeutic effects, as well as analyze the mechanism of MDR by molecular imaging modalities. In this review, the mechanisms involved in cancer MDR and recent advances of applying inorganic nanocarriers for MDR cancer imaging and therapy are summarized. The inorganic nanocarriers may circumvent cancer MDR for effective therapy and provide a way to track the therapeutic processes for real‐time molecular imaging, demonstrating high performance in studying the interaction of nanocarriers and MDR cancer cells/tissues in laboratory study and further shedding light on elaborate design of nanocarriers that could overcome MDR for clinical translation.

show abstract

“…Some molecular imaging prognostic markers are also emerging. Elevated glycolysis, measured by FDG PET, appears to be associated with more aggressive and lethal cancer in a variety of different tumor types (18)(19)(20)(21)(22)(23). The association can be quite striking.…”

Section: Applications Of Molecular Imaging To Cancer Prognosis Predimentioning

confidence: 99%

Molecular Imaging Research in the Outcomes Era

et al. 2007

View full text Add to dashboard Cite

SummaryAdvances in molecular imaging, combined with the goal of personalized cancer therapy, call for new approaches to clinical study design for trials testing imaging to guide therapy. The role of cancer imaging must expand and move beyond tumor detection and localization to incorporate quantitative evaluation of regional tumor phenotype. Imaging study design and outcome analysis must move beyond metrics designed to measure the performance for detection to include measures of prognosis, prediction of therapeutic success, and early therapy response. This implies changes in how studies are carried and out, and importantly in the regulatory oversight of cancer imaging. Demonstration that a biochemical or molecular imaging method correctly and accurately measures a specific biologic feature should be sufficient for approval for clinical trials. It may be possible that a combination of imaging procedures known to accurately depict tumor phenotype may be prognostic, even if the individual study cannot be directly validated against patient outcomes. Therefore, it will be important to be able to apply a range of possible imaging studies to different targeted cancer therapy trials. Academia and industry must work together with regulatory agencies and payers to facilitate well designed clinical studies, with appropriate outcome measures, to test the effectiveness of imaging in helping to direct cancer therapy. These will assure the appropriate use of imaging to direct treatment and make an important step towards individualized cancer therapy.

show abstract

Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review

Cited by 208 publications

References 42 publications

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007

Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics

Molecular Imaging Research in the Outcomes Era

Contact Info

Product

Resources

About